摘要
目的探讨缓激肽B1受体第3外显子1098A/G等位基因多态性在原发性女性高血压病患者中分布频率及其多态性与血管紧张素转换酶抑制剂(ACEI)降压疗效的关系。方法 150名原发性女性高血压病患者给予卡托普利治疗4周,记录治疗前后的血压水平。采用聚合酶链反应 (PCR)结合限制性内切酶检测缓激肽B1受体基因型。结果本研究中三种基因型AA、GA、GG频率分别为78．5％、19．6％、1．9％;ACEI治疗后AA和GA+GG基因型组收缩压分别下降(25．21±13． 69)mmHg与(34．50±12．56)mmHg,二组间比较有统计学意义(P<0．05)。结论缓激肽B1受体 1098A/G多态性与原发性女性高血压患者服用ACEI类药物的收缩压降低相关,携带G等位基因的患者卡托普利降压疗效优于野生型携带者。
Objective To investigate the 1098A/G gene polymorphism of the human bradykinin B1 receptor in essential hypertensive female patients and the relationship between 1098A/G gene polymorphism and antihypertensive response to ACEI. Methods One hundred fifty female patients with essential hypertensive were received ACEI for four weeks and compare with reduction of BP in different genomic . The1098A/G was genotyped by the polymerase chain reaction combined with restriction enzyme digestion methods. Results the genotype frequencies were 78.5% ,19.6% ,1.9% for AA ,GA,GG, respectively; The reduction of SBP in patients carrying AA and GA ＋ GG were 25.21 ± 13.69 mmHg and 34.50 ± 12.56 mm-Hg, respectively. A significant difference greater in patients among the two groups was found （P 〈 0.05 ） .Conclusion The reduction of SBP was significantly greater in patients with the G allele, suggesting that the1098 A/G polymorphism of human bradykinin B1 receptor extron was possibly related to the response toACEI in essential hypertensive patients.
出处
《中国分子心脏病学杂志》
CAS
2006年第1期33-37,共5页
Molecular Cardiology of China
